Quantinno Capital Management LP Has $4.49 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Quantinno Capital Management LP raised its position in Incyte Co. (NASDAQ:INCY - Free Report) by 106.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,968 shares of the biopharmaceutical company's stock after buying an additional 35,054 shares during the period. Quantinno Capital Management LP's holdings in Incyte were worth $4,493,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. MFA Wealth Advisors LLC bought a new stake in shares of Incyte during the second quarter worth $26,000. Brooklyn Investment Group acquired a new stake in Incyte in the 3rd quarter valued at about $30,000. Innealta Capital LLC bought a new position in shares of Incyte in the second quarter worth about $32,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Incyte during the third quarter worth approximately $33,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Incyte during the second quarter valued at approximately $36,000. 96.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on INCY shares. Wells Fargo & Company upped their price objective on Incyte from $62.00 to $68.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 30th. BMO Capital Markets reiterated an "underperform" rating and issued a $52.00 price target (up previously from $48.00) on shares of Incyte in a report on Wednesday, October 30th. Guggenheim upped their target price on shares of Incyte from $86.00 to $92.00 and gave the company a "buy" rating in a research report on Monday, September 16th. The Goldman Sachs Group raised their target price on shares of Incyte from $63.00 to $70.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Finally, Bank of America upgraded shares of Incyte from a "neutral" rating to a "buy" rating and increased their price objective for the company from $68.00 to $90.00 in a report on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Incyte currently has an average rating of "Hold" and an average target price of $77.16.

Insider Transactions at Incyte

In related news, EVP Barry P. Flannelly sold 3,680 shares of the company's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $79.68, for a total value of $293,222.40. Following the transaction, the executive vice president now owns 58,042 shares in the company, valued at approximately $4,624,786.56. This represents a 5.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas Tray sold 572 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the completion of the sale, the insider now owns 24,825 shares of the company's stock, valued at $1,562,485.50. This trade represents a 2.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,745 shares of company stock worth $1,311,687 in the last ninety days. Insiders own 17.60% of the company's stock.

Incyte Stock Up 1.3 %

NASDAQ:INCY traded up $1.00 during trading hours on Friday, reaching $75.92. 1,321,695 shares of the stock were exchanged, compared to its average volume of 2,419,518. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The stock has a market cap of $14.63 billion, a PE ratio of 542.32, a PEG ratio of 8.60 and a beta of 0.69. The firm has a 50 day moving average of $71.74 and a 200 day moving average of $65.76.

Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.19 by ($0.12). The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. Incyte's revenue was up 23.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.91 EPS. On average, equities analysts expect that Incyte Co. will post 0.4 earnings per share for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.